Menu Search
Equities

EKF Diagnostics Holdings PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LYF:FRA

EKF Diagnostics Holdings PLC

Actions
  • Price (EUR)0.28
  • Today's Change0.00 / 0.00%
  • Shares traded9.93k
  • 1 Year change+2.19%
  • Beta0.2551
Data delayed at least 15 minutes, as of Feb 17 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EKF Diagnostics Holdings plc is a diagnostics and biotechnology company specializing in the manufacturing and distribution of advanced medical technologies and patient-focused solutions. The Company develops and produces in-vitro diagnostic (IVD) devices and tests designed for use at or near the patient’s location. It provides a suite of products for diabetes management, including glucose monitoring systems and associated consumables. It offers devices, supplies, and consumables for measuring hemoglobin levels, including tools for detecting hemoglobin variants. It also develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and biomaterials. It provides precision fermentation, custom bioprocessing, and contract manufacturing services for pharmaceuticals and other biological products. It supplies beta-hydroxybutyrate (HB) products used in ketone detection to support the diagnosis of diabetic ketoacidosis and other clinical conditions.

  • Revenue in GBP (TTM)50.22m
  • Net income in GBP6.12m
  • Incorporated2002
  • Employees297.00
  • Location
    EKF Diagnostics Holdings PLCAvon HSE, 19 Stanwell RoadPENARTH CF64 2EZUnited KingdomGBR
  • Phone+44 292 071 0570
  • Fax+44 292 070 5715
  • Websitehttps://www.ekfdiagnostics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.